secwatch.observer — SEC 8-K summary
======================================

Issuer:     Protagonist Therapeutics, Inc (PTGX)
CIK:        0001377121
Form:       8-K
Filed at:   2023-08-03T23:59:59+00:00
Accession:  0001104659-23-087269
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Protagonist Q2 net loss $38.5M; JNJ-2113 advances to Phase 3 in psoriasis
-------------------------------------------------------------------------

- Net loss of $38.5M ($0.68/share) in Q2 2023 vs $41M loss in Q2 2022; cash $313.4M at June 30.
- JNJ-2113 Phase 2b FRONTIER 1 met all endpoints; 78.6% PASI 75 at 100mg BID; moving to Phase 3 psoriasis and Phase 2b UC.
- Rusfertide Phase 2 REVIVE positive results presented at EHA2023; Phase 3 VERIFY enrollment continues targeting Q1 2024 completion.
- Completed $115M equity financing in April 2023.
- License revenue $0 vs $0.9M in Q2 2022 as prior period included $25M milestone.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1377121/000110465923087269/0001104659-23-087269-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1377121/000110465923087269/tm2322752d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-087269

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer